Edaravone Prevents Retinal Degeneration in Adult Mice Following Optic Nerve Injury.
Invest Ophthalmol Vis Sci
; 58(11): 4908-4914, 2017 09 01.
Article
em En
| MEDLINE
| ID: mdl-28973341
ABSTRACT
Purpose:
To assess the therapeutic potential of edaravone, a free radical scavenger that is used for the treatment of acute brain infarction and amyotrophic lateral sclerosis, in a mouse model of optic nerve injury (ONI).Methods:
Two microliters of edaravone (7.2 mM) or vehicle were injected intraocularly 3 minutes after ONI. Optical coherence tomography, retrograde labeling of retinal ganglion cells (RGCs), histopathology, and immunohistochemical analyses of phosphorylated apoptosis signal-regulating kinase-1 (ASK1) and p38 mitogen-activated protein kinase (MAPK) in the retina were performed after ONI. Reactive oxygen species (ROS) levels were assessed with a CellROX Green Reagent.Results:
Edaravone ameliorated ONI-induced ROS production, RGC death, and inner retinal degeneration. Also, activation of the ASK1-p38 MAPK pathway that induces RGC death following ONI was suppressed with edaravone treatment.Conclusions:
The results of this study suggest that intraocular administration of edaravone may be a useful treatment for posttraumatic complications.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Degeneração Retiniana
/
Antipirina
/
Sequestradores de Radicais Livres
/
Traumatismos do Nervo Óptico
Limite:
Animals
Idioma:
En
Revista:
Invest Ophthalmol Vis Sci
Ano de publicação:
2017
Tipo de documento:
Article